NexMed

NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, arthritis, sexual disorders and more. NexMed offers large pharmaceutical companies the opportunity to incorporate NexACT® into their existing drugs, allowing these companies to save considerably on R&D costs while developing new patient-friendly transdermal products and extending patent lifespans and brand equity. NexMed has also made significant strides with its proprietary anti-fungal drug, NM10060. In September of 2005, the Company announced a partnership with Novartis International Pharmaceutical Ltd. for the licensing and marketing NM10060. Other leading treatments under development include Alprox-TD for the treatment of erectile dysfunction, Femprox, a topical cream cure for female sexual dysfunction. NexMed’s drugs incorporate NexACT® drug delivery technology which offers several competitive advantages in the treatment of various illnesses including: fast onset of action, patient friendly route of delivery, little or no side effects and improved clinical efficacy. The NexACT® penetration enhancers are designed to be structurally similar to and biologically compatible with the skin structure, are non-toxic, biodegradable, and enable drug candidates to efficiently overcome the skin or mucosal membranes. NexMed’s NexACT technology has wide-ranging applicability in the development of transdermal dosage forms such as patches, creams, gels, ointments, lotions, solutions and intranasal sprays.

Contact Details: 89 Twin Rivers Drive East Windsor NJ 08520 United States of America Tel: (609) 371-8123 Fax: (609) 426-9116 Email: ccantwell@rubensteinir.com WWW: www.nexmed.com/

Loading...

BioNews Results for NexMed:
Dutton Associates Announces Investment Opinion: NexMed Lowered To Speculative Buy Rating In Research Note By D	DiGiTAL50:  Sep 4 2008 8:02PM Matching: nexmed
Nexmed Announces Decision for NM100060	PipelineReview:  Sep 3 2008 3:43PM Matching: nexmed
NexMed: Study Results Do Not Merit NDA	FDA News:  Sep 2 2008 9:45PM Matching: nexmed
NexMed: Study Results Do Not Merit NDA	FDA News:  Sep 2 2008 9:03PM Matching: nexmed
NexMed Shares Fall Hard as Novartis Nixes NDA	Calibre Macro World:  Aug 27 2008 11:45PM Matching: nexmed
Promote your company here: BioNewsCast - Press Release Distribution	→View more NexMed news.

NexMed Patents:
US Patent No.	Title
7105571	Prostaglandin compositions and methods of treatment for male erectile dysfunction
6046244	Topical compositions for prostaglandin E.sub.1 delivery
6083250	Apparatus and method for inhibiting lesion formation by selectively treating the prodromal stage of the lesion with a pulsatile electrical stimulation
6083996	Topical compositions for NSAI drug delivery
6118020	Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
→View more NexMed patents.

NexMed (NEXM) Financial information Links from Barchart
NEXM Quote from from Barchart.com
NEXM Chart from from Barchart.com
NEXM Profile from from Barchart.com
NEXM Opinion from from Barchart.com
→View more NexMed finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 178 times since April 2007, the link to the organisation's website has been followed 32 times

Recent Search Terms used to find this page: @nexmed.com | www.nexmed | nexmed patents | @nexmed.com | .

Search for more companies in East Windsor

Search for more companies in NJ

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for NexMed